WallStSmart

AlphaTime Acquisition Corp Ordinary Shares (ATMC)vsDrugs Made In America Acquisition II Corp. Ordinary Shares (DMII)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DMII leads profitability with a 0.0% profit margin vs 0.0%. DMII earns a higher WallStSmart Score of 23/100 (F).

ATMC

Avoid

22

out of 100

Grade: F

Growth: 3.7Profit: 4.0Value: 3.0Quality: 5.0

DMII

Avoid

23

out of 100

Grade: F

Growth: 4.3Profit: 4.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATMCSignificantly Overvalued (-2788.9%)

Margin of Safety

-2788.9%

Fair Value

$0.54

Current Price

$15.60

$15.06 premium

UndervaluedFair: $0.54Overvalued

Intrinsic value data unavailable for DMII.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATMC0 strengths · Avg: 0/10

No standout strengths identified

DMII0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ATMC4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$38.02M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.0%3/10

ROE of 2.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

DMII4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$653.78M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ATMC

ATMC has a balanced fundamental profile.

Bull Case : DMII

DMII has a balanced fundamental profile.

Bear Case : ATMC

The primary concerns for ATMC are Revenue Growth, Market Cap, Return on Equity. A P/E of 186.3x leaves little room for execution misses.

Bear Case : DMII

The primary concerns for DMII are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

DMII is growing revenue faster at 0.0% — sustainability is the question.

ATMC generates stronger free cash flow (-5,067), providing more financial flexibility.

Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DMII scores higher overall (23/100 vs 22/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AlphaTime Acquisition Corp Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

AlphaTime Acquisition Corp (ATMC) is a special purpose acquisition company (SPAC) focused on identifying and merging with innovative enterprises across high-growth sectors. Backed by a solid capital foundation and a seasoned management team, ATMC aims to maximize shareholder value through strategic partnerships with businesses that demonstrate substantial growth potential. By concentrating on emerging technology and evolving consumer trends, the company is positioned to create enduring value for its stakeholders while employing a disciplined evaluation process to navigate the dynamic landscape of mergers and acquisitions.

Drugs Made In America Acquisition II Corp. Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company (SPAC) focused on merging with innovative firms within the pharmaceuticals and biotechnology sectors to enhance domestic drug manufacturing capabilities. Leveraging the extensive expertise of its management team, DMII identifies and executes strategic transactions that align with rising market demands and prioritize sustainable practices. Through its commitment to fostering resilient supply chains and advancing U.S. healthcare self-sufficiency, DMII aims to deliver sustained value for its shareholders and contribute to the long-term growth of the American pharmaceutical landscape.

Want to dig deeper into these stocks?